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Although tumor genomic profiling has identified small subsets of gastric cancer (GC) patients
with clinical benefit from anti-PD-1 treatment, not all responses can be explained by tumor
sequencing alone. We investigate epigenetic elements responsible for the differential
response to anti-PD-1 therapy by quantitatively assessing the genome-wide chromatin
accessibility of circulating CD8+ T cells in patients’ peripheral blood. Using an assay for
transposase-accessible chromatin using sequencing (ATAC-seq), we identify unique open
regions of chromatin that significantly distinguish anti-PD-1 therapy responders from non-
responders. GC patients with high chromatin openness of circulating CD8+ T cells are
significantly enriched in the responder group. Concordantly, patients with high chromatin
openness at specific genomic positions of their circulating CD8+ T cells demonstrate sig-
nificantly better survival than those with closed chromatin. Here we reveal that epigenetic
characteristics of baseline CD8+ T cells can be used to identify metastatic GC patients who
may benefit from anti-PD-1 therapy.
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Studies of immune cell exhaustion and tumor-infiltratinglymphocyte (TIL) dysfunction due to persistent antigenicstimuli (e.g., chronic viral infection and tumors) have
revealed cell surface proteins that are involved in the functional
impairment of immune cells; these proteins include multiple co-
inhibitory or checkpoint receptors, such as cytotoxic T lympho-
cyte antigen-4 (CTLA-4, CD152), programmed death-1 (PD-1,
CD279), T cell immunoglobulin and mucin-domain containing-3
(TIM-3), and lymphocyte-activation gene (LAG-3)1. Conse-
quently, clinical trials involving in vivo administration of neu-
tralizing antibodies (Abs) against immune checkpoints (i.e.,
immune checkpoint inhibitors [ICIs]) have been conducted to
functionally restore T cells1,2. These ICI drugs are currently
approved for those patients who have failed at least two prior
lines of systemic chemotherapy in metastatic gastric cancer
(mGC)3,4. Pembrolizumab has been provisionally approved based
on biomarker selection (PD-L1 immunohistochemistry [IHC]
status) while nivolumab has been approved without biomarker
selection. We recently reported on phase II study of single agent
pembrolizumab in mGC which identified remarkable and durable
response in the microsatellite instability-high (MSI-H) and
Epstein–Barr virus (EBV) positive GC subtypes5. However, the
incidence of MSI-H and EBV positivity in mGC is relatively low
in the range between 2 to 4%. Hence, we need to understand who
may potentially benefit from ICI beyond MSI-H and EBV posi-
tivity in their tumor characteristics in order to increase the rate of
GC patients with clinical benefit.
Recent studies have mainly focused on tumor genomics and
PD-L1 scores as predictors for response to ICIs6,7. Although an
in-depth understanding of the regulation of tumor–host inter-
actions has been underscored to optimize treatment strategies in
immunotherapy, the role of circulating CD8+ T cells have not
been extensively investigated in GC patients, especially in corre-
lation to treatment response. In the present study, we investigate
the correlation between changes in circulating CD8+ T cells
(baseline and 3 to 6 weeks pembrolizumab) and response to anti-
PD-1 treatment using flow cytometric analysis in our previous
phase II pembrolizumab cohort5. Next, we analyze the baseline
CD8+ T cells using an assay for transposase-accessible chromatin
using sequencing (ATAC-seq)8 to further characterize the epi-
genetic landscape of circulating CD8+ T cells which may reflect
host-tumor interactions. Chronic stress9–11 caused by factors
such as pathogens, microbiota, acidity, hypoxia, glucose depri-
vation, and the tumor microenvironment can cause epigenetic
changes12,13 that lead to subtle to profound alterations in the
immune system14,15. These host-tumor interactions can alter
epigenetic characteristics of circulating CD8+ T cells which may
increase or decrease response to anti-PD-1 treatment in cancer
patients16,17.
Our analysis show that chromatin openness in baseline circu-
lating CD8+ T cells distinguish responder group (R) from non-
responder group (NR) in the discovery cohort and the validation
cohort. All EBV-positive patients and MSI-H patients who
responded to pembrolizumab have high openness of chromatin at
specific genomic positions of baseline CD8+ T cells. Furthermore,
mGC patients with high openness chromatin of CD8+ T cells
show longer PFS following anti-PD-1 treatment when compared
to those with closed chromatin. These results present that
openness of chromatin at specific genomic positions of baseline
circulating CD8+ T cells can predict clinical outcome to treat-
ment response following anti-PD-1 treatment.
Results
Clinical characteristics of patients with gastric cancer. For
discovery cohort, cryopreserved blood lymphocyte samples from
mGC patients participating in a phase II pembrolizumab
monotherapy clinical trial (clinicaltrials.gov identifier
NCT#02589496)5 were used in this study. Of the 61 patients
enrolled, only viable blood lymphocyte samples from 32 patients
had baseline, 1, 2 cycles post-pembrolizumab blood lymphocytes
collected were used for further analysis. For validation cohort, 52
mGC patients who received pembrolizumab for third-line treat-
ment were consented for baseline blood collection. Clinical
characteristics of all patients with mGC are provided in Supple-
mentary Tables 1 and 2. In total, 84 samples were analyzed with
ATAC sequencing. Of 84 patients, 11 patients were MSI-H GC
patients (8 responders) and 10 patients were EBV-positive GC (5
responders). In an entire cohort, 28 of 84 patients (33.3%) were
responders to anti-PD-1 therapy; 15 of 28 (53.6%) responders
were non-EBV or MSS patients. Taken together, 53.6% of the
patients lacked of known predictive factors such as MSI-H or
EBV-positive in their tumor specimen but still responded to anti-
PD-1 therapy. PD-L1 IHC (immunohistochemistry) score using
22C3 antibody is provided in all available tumor specimen
(Supplementary Tables 1 and 2).
In the flow cytometric analysis for discovery cohort, there was
no significant difference in the frequencies of CD8+ T cells and
PD-1+CD8+ T cells in responders (complete response [CR),
partial response [PR]) or non-responders (stable disease [SD] or
progressive disease [PD]) to pembrolizumab (Fig. 1a–b and
Supplementary Fig. 1a). In flow cytometric analysis of pre- and
post-treatment (3 to 6 weeks) samples, the proportion of Ki-67+
CD8+ T cells (% proliferating cells [Ki-67+], baseline 3.42 ± 0.33,
post-treatment 6.72 ± 1.15, mean ± standard error of the mean
[SEM], P= 0.008, Wilcoxon signed rank test) increased after
pembrolizumab (Fig. 1c, left panel). Further, the frequency (%) of
proliferating PD-1+CD8+ T cells (baseline 5.22 ± 0.76, post-
treatment 14.4 ± 1.78, mean ± SEM, P < 0.0001, Wilcoxon signed
rank test) increased after pembrolizumab (Fig. 1c, middle panel).
However, there was no substantial difference in percentage of Ki-
67+ in PD-1+CD8+ T cells among responders and non-
responders (Fig. 1c, right panel); this finding is consistent with
the results of previous studies18,19.
Normalization process of ATAC-seq data among samples.
CD8+ T cells isolated from baseline blood samples of patients
enrolled in a phase II pembrolizumab trial5 were subjected to
genome-wide chromatin assay for ATAC-seq (Fig. 2a). We
developed a normalization method to quantitatively compare the
ATAC-seq data. Given the increased sensitivity, reproducibility,
and large dynamic range of ATAC technology, the necessity of
normalizing these large ATAC-seq datasets exceeded the
requirements of ATAC library and deep-sequencing quality
guidelines (Supplementary Table 3)20,21. We applied a normal-
ization process developed for massive computation loads22,23. We
performed two critical selection steps to discover distinctive peaks
differentiating responders from non-responders within our ana-
lysis of human genome (hg19)-mapped ATAC-seq data (Fig. 2b).
The first step was the selection of a universal control to identify
consensus peaks to adopt as normalization controls (Fig. 2b–d).
We matched 4,798 consensus ATAC peaks among previously
studied CD8+ T-cell subsets17 with DNase I hypersensitive (DH)
uniform peaks from the ENCODE project24 located on the TSS or
5′-untranslated regions (UTR), which are transcriptionally active
regions of the genome. Among these, 533 consensus ATAC peaks
appeared in the ATAC-seq CD8+ T-cell data used in this study.
To obtain more accurate normalization controls from selected
consensus ATAC peaks, we adopted a strategy of selecting peaks
with low coefficients of variation (CVs), resulting in high simi-
larity due to low variability among ATAC peaks for the samples.
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Thus, we selected 232 ATAC peaks, of which 20 (Supplementary
Fig. 2 and Supplementary Data 1) were highly evolutionarily
conserved among 17 species (Fig. 2d) and could be useful for
epigenomic studies with other cell types (Supplementary Fig. 3a–c).
Finally, we applied these peaks for normalization within a cohort.
We defined the normalization factor (F) of each sample as the
mean height (h) of all samples in a cohort (C) divided by the height
of a corresponding sample (Supplementary Fig. 4). The use of a
control set to quantify and compare ATAC-seq data could enhance
the applicability of ATAC-seq data.
Epigenetic signatures for pembrolizumab treatment. Next, we
identified differential peaks of chromatin regions in the ATAC-
seq between responders and non-responders to pembrolizumab.
Briefly, peaks in the ATAC-seq reflect the “openness” in chro-
matin structure which can be influenced by tumor-host interac-
tions. We identified 2,560 differential peaks using three peak
callers25–27 using peak-calling packages (Supplementary Table 4
and Fig. 3a). The area (A) values of 2,560 differential peaks in
each sample were then normalized using the F value determined
in the first step, allowing quantitative comparisons among
Fig. 1 PD-1+CD8+ T cell proliferation after pembrolizumab treatment. a Outline of flow cytometric analysis and transposase-accessible chromatin using
sequencing (ATAC-seq)-based molecular diagnosis. Peripheral blood mononuclear cells (PBMCs) from patients with metastatic gastric cancer (mGC)
were stained with antibodies (Abs) to CD8, programmed death-1 (PD-1), and Ki-67 at baseline and after 2 cycles of pembrolizumab treatment. MSS:
microsatellite stability; EBV: Epstein–Barr virus; PD-L1: programmed death-ligand 1; IHC: immunohistochemistry. b Frequency of CD8+ T cells and PD-1+
CD8+ T cells in patients with mGC at baseline (GC PD, n = 13 patients; SD, n = 16; PR, n = 4; CR, n = 2). Representative zebra plots showing the frequency
of PD-1+CD8+ T cells. Bars represent as means + SEM, Data were compared using the one-way ANOVA test (left graph: P= 0.819, F(2, 32)= 0.2008;
right graph: P= 0.311, F(2, 32)= 1.213). n.s., not significant. PD: progression disease; SD: stable disease; PR: partial response; CR: complete response.
c Representative zebra plots showing the Ki-67 expression of CD8+ T cells and CD8+ T-cell subsets (center), PD-1-CD8+ and PD-1+CD8+ T cells, in GC
patient at baseline and pembrolizumab treatment. Representative zebra plots showing the Ki-67 expression of PD-1+CD8+ T cells in PD, SD, PR+ CR
groups.
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samples. The F value of each sample (Supplementary Fig. 5a) and
the corresponding area value (Supplementary Fig. 5b) were sta-
bilized by the number of controls. ATAC-seq data for 2,560
differential peaks were consistently normalized with F values
calculated using three sets of controls, ranked −5, −20, and −50
(Supplementary Table 5) to obtain a normalized area value (F ×
A). We used these normalized area values to further select dif-
ferential peaks (Fig. 3a) as followed: 68, 121 and 149 peaks by
three sets of controls respectively satisfied the criteria of average
area value of peaks > average area value of total peaks and P <
0.05 (Mann–Whitney U test). Of these peaks, 67 shared by three
sets of controls were rank-ordered by differences in the average
values (Supplementary Fig. 6). For example, a control set of 20
reduced the difference in overall peak increases (corresponding to
area values) among samples, allowing quantitative sample com-
parison (Supplementary Fig. 7). Among the 67 differential peaks
(Supplementary Data 2), we visualized nine representative peaks
using the University of California, Santa Cruz (UCSC) genome
browser (Fig. 3b); these peaks were located near active regulatory
elements28, suggesting that they may be regulated by various
transcription factors (defined in the ENCODE projects and
Supplementary Fig. 8). To explore the predictability of the
selected peaks as diagnostic targets, we performed receiver
operating characteristic (ROC) analysis of these targets (Fig. 3c).
The nine representative targets showed statistically fair diagnostic
ability29 with the area under the ROC curve (AUROC) ≥ 0.7 and
target sensitivity and specificity of 88.0 ± 3.6% and 70.0 ± 3.9%
(mean ± SEM), respectively (Fig. 3d).
Chromatin openness to response to pembrolizumab treatment.
Chromatin openness of differential peaks in CD8+ T cells dis-
tinguished between a responder group (R) and a non-responder
group (NR) in the discovery (discovery cohort, n= 32) (Fig. 4a
and Supplementary Table 6). All EBV-positive patients and MSI-
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H patients who responded to pembrolizumab had high openness
of chromatin at specific genomic positions of baseline CD8+
T cells (Fig. 4a). One MSI-H patient (SS20) with de novo resis-
tance to pembrolizumab had closed chromatin at the corre-
sponding genomic positions of baseline CD8+ T cells (Fig. 4a). In
all, patients with high chromatin openness of baseline circulating
CD8+ T cells were enriched in responder group when compared
to non-responder group with sensitivity of 87.8 ± 3.6% (mean ±
SEM) and specificity of 69.7 ± 3.6% (Fig. 4a, Supplementary
Table 6 and Supplementary Fig. 9). Nine regions with opened
chromatin were sorted in descending order of accuracy values
(Supplementary Table 7); this order was used to convert ATAC-
seq data openness values to a weighted score (see Methods).
When all 9 significant peaks were summated, sensitivity was
100.0% and specificity was 90.9% for distinguishing R from NR to
pembrolizumab (Fig. 4b, c). In the discovery set, patients with
high chromatin openness in baseline circulating CD8+ T cells
(n= 12, 12 of 32, 37.5%) (Fig. 4b) demonstrated longer median
PFS (not reached) than those with closed chromatin at the cor-
responding genomic position of circulating CD8+ T cells (median
PFS, range, 2.7 months; n= 20, 62.5% of patients) (Fig. 4d).
Evaluation of chromatin openness to predict anti-PD-1 therapy.
In the validation cohort (n= 52), patients with high chromatin
openness of baseline circulating CD8+ T cells were enriched in
responder group when compared to non-responder group
regardless (Fig. 5a, Supplementary Table 8 and Supplementary
Fig. 10). All MSI-H (n= 4) and EBV-positive (n= 2) patients who
responded to pembrolizumab had high chromatin openness. SS007
patient with EBV-positive GC who had closed chromatin openness
did not respond to anti-PD-1 treatment. Of 13 non-EBV, MSS
patients who responded, 11 (86%) patients had high chromatin
openness. Four of the nine selected chromatin “open” regions
showed statistically significant differences in PFS in the validation
cohort, but nonetheless, each median PFS was greater in patients
with high chromatin openness than in patients with closed chro-
matin openness. The nine targets showed reasonable discriminative
ability (AUROC > 0.544) and target sensitivity and specificity of
80.2 ± 3.5% and 46.7 ± 3.9% (mean ± SEM), respectively (Supple-
mentary Table 8 and Supplementary Fig. 10). The combination of
these peaks enhanced the discriminative ability in the validation
cohort (AUROC 0.717) and sensitivity and specificity of this
combination was reached to 88.9% and 58.8%, respectively
(Fig. 5b). Accordingly, the combination of all 9 peaks predicted
response to pembrolizumab very well (Fig. 5c) and reflected in the
clinical outcome in terms of PFS (Fig. 5d; high openness versus
closed openness; median PFS 7.6 months versus 1.6 months; P <
0.001). Taken together, openness of chromatin at specific genomic
positions of baseline circulating CD8+ T cells predicted better
clinical outcome to pembrolizumab in terms of PFS in both dis-
covery cohort and validation cohort.
Discussion
In this study, we demonstrated that openness of chromatin in
circulating CD8+ T cells predicts better treatment outcome to
pembrolizumab in mGC patients. All EBV-positive and MSI-H
patients who responded to pembrolizumab had considerable
openness in their circulating CD8+ T cell’s chromatin. Currently,
there is no perfect biomarker which predicts response to ICIs.
One of the working hypotheses is the influence of circulating
CD8+ T cells which need to be actively recruited to tumor sites
upon ICI treatment but also functionally activated. These circu-
lating CD8+ T cells may be epigenetically imprinting their traces
under various chronic stresses during cancer development or
progression7.
In this study, we analyzed circulating CD8+ T cells in known
responders to pembrolizumab using samples from phase II trial5.
Then, we tested the established analysis algorithm in 52 GC
patients who received pembrolizumab as practice. EBV positivity
and MSI-H are two pathologic factors to predict response to
immune check point inhibitors in GC. However, this subset is
relatively rare (less than 5% of all metastatic GC patients) but the
response to ICI is also observed in non-EBV, MSS subset. In
addition, even within EBV-positive or MSI-H patient cohort, the
response rate is 50% which suggests that there are other influ-
ential factors to determine response to immune checkpoint
inhibitors. Of 13 non-EBV, MSS responders, 11 (86%) patients
had high chromatin openness in their circulating CD8+ T cells.
Although definitive conclusion cannot be drawn from this study
due to small sample size, this is the first study to demonstrate that
circulating T-cell characteristics may contribute in predicting
response to ICI.
Fig. 2 Outline of assay for transposase-accessible chromatin using sequencing (ATAC-seq)-based molecular diagnosis and peak selection processes.
a To identify biomarkers that can predict the benefits of anti-PD-1 therapy, we processed PBMCs from patients with mGC by generating an ATAC library
and performing deep sequencing. The transposition reaction resulted in fragmented genomic DNA; transposons were inserted by Tn5 transposases into
open and accessible chromatins. Following ATAC library sequencing and mapping to the human genome, genome-wide analysis revealed differences
between responders and non-responders to anti-PD-1 therapy. MSS: microsatellite stability; EBV: Epstein–Barr virus; PD-L1: programmed death-ligand 1;
IHC: immunohistochemistry. b After ATAC library generation, each library pool was quantified using a Bioanalyzer and sequenced on a single lane of the
NextSeq 500 system using 75-bp single reads. Sequencing read (fastq) files were mapped using the human genome database (hg19) and Bowtie v.
2.0 software. Further analysis was performed in two stages: (1) control peak selection to identify consensus peaks among CD8+ T-cell subsets known as
DNase I hypersensitive (DH) sites, followed by normalization of peaks from each patient using control peaks; and (2) predictive peak selection to
distinguish response and non-response to anti-PD-1 therapy after normalization of the selected differential peaks. NGS: next generation sequencing; hg:
human genome. c Universal control peak selection and normalization. After peak calling, universal control selection was performed to identify consensus
peaks as normalization controls. In total, 4,798 consensus assays were matched for transposase-accessible chromatin (ATAC) peaks among previously
studied CD8+ T-cell subsets with DNase I hypersensitive (DH) uniform peaks from the ENCODE project; these peaks were located on transcriptional start
site (TSS) or 5’-untranslated regions (UTR). In addition, 533 consensus ATAC peaks were detected in ATAC-seq CD8+ T-cell data used in this study. To
identify accurate normalization controls among selected consensus ATAC peaks, the coefficient of variation (CV; i.e., the ratio of the standard deviation
[SD] to the mean) was used to define the extent of ATAC peak variability among samples and peaks with mono- and di-nucleosome patterns. First, the
area of the peak was calculated using the area of base pairs within the range of the peak; these areas were used to calculate CV values for each peak. In
total, 232 ATAC peaks were detected which satisfied two criteria: low variance (CV < 0.3) and uniqueness of peak width (< 500 bp). Notably, the top 20
peaks in terms of average peak area were highly evolutionarily conserved among 17 species; these peaks, which could be useful for genomic studies of
other species, were used to calculate the within-cohort normalization factor (F). PB: peripheral blood; EM: effector memory; CM: central memory. d Two
representative control peaks shown in a genome browser. Conservation levels among 17 species are shown at the bottom of the corresponding peak. The
y-axis shows read counts.
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It has been shown in the previous report17 that chromatin
states defined tumor-specific T-cell dysfunction and reprogram-
ming. They have shown that using ATAC-seq and RNA-seq of
TILs and CD8+ T cells, cancer patients who do not respond to
ICIs had lymphocytes in a plastic state which are not amenable to
reprogramming. In our study, when openness of chromatin at
specific genomic position is high in circulating CD8+ T cells,
patients responded to pembrolizumab. We speculate that these
patients have CD8+ T cells in a plastic state with less dysfunction
and amenable to reprogramming upon blockade of PD-1. In
addition, the enrichment of the transcription factor binding
motifs located within significant nine representative peaks
Fig. 3 Selection of control and differential peaks, followed by normalization. a We selected 2,560 differential peaks that distinguished between a
responder group (complete response plus partial response, CR+ PR) and a non-responder group (progressive disease, PD) using three peak callers: the
HOMER suite, MACS2, and CisGenome. These peaks were normalized by control peaks (Supplementary data 1), then subjected to selection procedures.
Chromatin accessibility heatmaps with normalized peak area values by 20 controls (rows) and patients (columns) were displayed as a representative. C5,
C20 and C50 indicate 5 controls, 20 controls and 50 controls, respectively. Peaks were ranked by relative distance between the two groups as described in
Methods. Relative minimum and maximum area values are indicated in navy and yellow, respectively. b Genome browser tracks show nine differential
peaks (i.e., openness) as targets in a responder group (CR+ PR, green) and a non-responder group (PD, red). Numbers above each peak denote target IDs.
The y-axis shows the adjusted read count, calculated using a normalization factor (F). Scale bar indicates 400 base pairs (bp) of nucleotides. c Receiver
operating characteristic (ROC) curves for the nine targets in the discovery cohort. Adjacent are target IDs with the areas under the ROCs (AUROCs) of the
nine targets. The area under the diagonal reference line is filled. d Determination of threshold values for the nine targets. Target IDs are arranged in
descending order of relative mean difference between responder (CR+ PR) and non-responder (PD) groups. For each target, the threshold value indicates
the optimized guideline calculated by the online Cutoff Finder tool, allowing prediction of response to anti-PD-1 therapy. Responders and non-responders
were counted as the number of samples above or below the threshold, respectively, to determine sensitivity and specificity.
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(Supplementary Fig. 8) could be linked to activation of T cell
receptor signaling pathway such as nuclear factor of activated T cell
(NFAT), adaptor-related protein complex 1 (AP-1) and nuclear
factor κB (NF-κB). These findings suggest that chromatin openness
of specific genomic positions in exhausted CD8+ T cells is probably
associated with the restoration of T-cell functions by PD-1 block-
ade. Thus, we plan to further characterize CD8+ T cells with single
cell RNA-seq and ATAC-seq analysis to identify gene-specific
targets for activation of CD8+ T cells upon ICI treatment.
Taken together, the chromatin state of circulating CD8+ T cells
was influential on response to ICI in mGC patients. Tremendous
effort has been focused on profiling patient’s tumor; nevertheless,
we demonstrated that mGC patients with high openness at spe-
cific genomic positions of their circulating CD8+ T-cell chro-
matin responds better to pembrolizumab with longer PFS. The
functional activation of the CD8+ T cells with high open chro-
matin at specific genomic positions is currently being investi-
gated. While further validation of the findings is underway,
Fig. 4 Correlation between chromatin openness of circulating CD8+ T cells and treatment response to anti-PD-1 therapy (discovery cohort, n = 32).
a Patients with normalized area values above and below the threshold are indicated by filled (blue) and open circles, respectively, at each target peak.
Sensitivity and specificity were calculated for a responder group (R, CR+ PR) and a non-responder group (NR, PD+ SD). MSI: microsatellite instability;
MSS: microsatellite stability; EBV: Epstein–Barr virus. PD: progression disease; SD: stable disease; PR: partial response; CR: complete response. b Nine
targets in descending order of accuracy (ACC) were statistically evaluated in combination. After normalized areas above and below the threshold had been
converted to 1 and 0, respectively, these binary values were multiplied by values ranging from 1 (lowest) to 9 (highest) on the accuracy rank, to obtain a
weighted score. Instead of normalized area values, the weighted scores were used for further ROC analysis and to calculate a threshold for each
combination of the nine targets using Cutoff Finder. AUROC indicates the area under receiver operating characteristic. c Openness scores (weighted score)
for a responder group (R, CR+ PR) and a non-responder group (NR, PD+ SD) with normalized area values were displayed in a dot plot (left graph). Bars
and error bars indicate the mean area value and SEM for each group (n = 10 from R and n = 22 from NR). P-value < 0.0001 was obtained using the two-
sided Mann–Whitney U test. Arb. units indicate arbitrary units. Waterfall plots according to the openness of circulating CD8+ T cells were displayed in the
middle panel. Green: CR+ PR; Orange: SD: Red: PD. d Threshold value of combination with the nine targets was used to determine clinical outcomes of
anti-PD-1 therapy using progression-free survival (PFS) curve. Tumor progression scores for patients above (n = 12) and below (n = 20) the threshold are
shown in blue and red, respectively. Median PFS (mPFS) time was calculated using Kaplan–Meier survival analysis. Survival curves of the two groups were
compared using the two-sided log-rank (Mantel–Cox) test in a single comparison (P < 0.0001). n.r., not reached.
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epigenetic landscape of CD8+ T cells should be actively investi-
gated in ICI-treated cancer patients.
Methods
Study design and participants. This study was approved by the Institutional
Review Boards of Seoul National University Hospital (no. 0905-014-280) and
Samsung Medical Center (no. 2015-09-053). Written informed consent was
obtained from all patients, in accordance with the Declaration of Helsinki. Patients
participating in the clinical trial (clinicaltrials.gov identifier NCT#02589496)5 were
designated as the discovery cohort. For validation cohort, we prospectively
recruited mGC patients (n= 52) who were undergoing anti-PD-1 therapy with
pembrolizumab and collected peripheral blood before treatment. Clinical char-
acteristics of all patients with mGC are provided in Supplementary Tables 1 and 2.
Fig. 5 Correlation between chromatin openness of circulating CD8+ T cells and treatment response to anti-PD-1 therapy (validation cohort, n = 52).
a Patients with normalized area values above and below the threshold are indicated by filled (blue) and open circles, respectively, at each target peak.
Sensitivity and specificity were calculated for a responder group (R, CR+ PR) and a non-responder group (NR, PD+ SD). MSI: microsatellite instability;
MSS: microsatellite stability; EBV: Epstein–Barr virus. PD: progression disease; SD: stable disease; PR: partial response; CR: complete response. b Nine
targets in descending order of accuracy (ACC) were statistically evaluated in combination. After normalized areas above and below the threshold had been
converted to 1 and 0, respectively, these binary values were multiplied by values ranging from 1 (lowest) to 9 (highest) on the accuracy rank, to obtain a
weighted score. Instead of normalized area values, the weighted scores were used for further ROC analysis and to calculate a threshold for each
combination of the nine targets using Cutoff Finder. AUROC indicates the area under receiver operating characteristic. c Openness scores (weighted score)
for a responder group (R, CR+ PR) and a non-responder group (NR, PD+ SD) with normalized area values were displayed in a overlaid dot plot and bar
graph (left graph). Bars and error bars indicate the mean area value and SEM for each group (n = 18 from R and n = 34 from NR). P-value = 0.0008 was
obtained using the two-sided Mann–Whitney U test. Arb. units indicate arbitrary units. Waterfall plots according to the openness of circulating CD8+
T cells were displayed in the middle panel. Green: CR+ PR; Orange: SD: Red: PD. d Threshold value of combination with the nine targets was used to
determine clinical outcomes of anti-PD-1 therapy using progression-free survival (PFS) curve. Tumor progression scores for patients above (n = 30) and
below (n = 22) the threshold are shown in blue and red, respectively. Median PFS (mPFS) time was calculated using Kaplan–Meier survival analysis.
Survival curves of the two groups were compared using the log-rank (Mantel–Cox) test in a single comparison (P= 0.0005). n.r., not reached.
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Tumor specimen microsatellite instability-high (MSI-H) or EBV positivity status
information was obtained from our previous report5. Written informed consent
was obtained from all patients, in accordance with the Declaration of Helsinki.
Flow cytometry and cell sorting. Peripheral blood mononuclear cells (PBMCs)
were purified from heparinized peripheral blood using a Ficoll–Histopaque gra-
dient (1.077 g/mL; GE Healthcare Life Sciences, Piscataway, NJ, USA) and stored in
liquid nitrogen after suspension in freezing media including 50% fetal bovine
serum, 10% dimethyl sulfoxide, and 40% RPMI-1640 (Invitrogen, Carlsbad, CA,
USA) until further analysis30. To obtain CD8+ T cells, thawed PBMCs were stained
with appropriate Abs and sorted using the FACSAria III cell sorter (BD Bios-
ciences, San Jose, CA, USA).
Abs used for flow cytometry and sorting included Alexa 700–anti-CD8 (1:100;
Cat.No. 557945; clone, RPA-T8), allophycocyanin–anti-PD-1 (1:5; Cat. No.
558694; clone, MIH4) and FITC–anti-Ki-67 (1:25; Cat. No. 51-36524X; clone, B56)
(all from BD Biosciences). Staining intracellular molecules was performed after
permeabilization using a Cytofix/Cytoperm kit (BD Biosciences). Stained cells were
analyzed using an LSR II flow cytometer (BD Biosciences) with the FACSDiva
software. Data were analyzed using the FlowJo software (TreeStar, Ashland,
OR, USA).
ATAC-seq library preparation and high-throughput sequencing. ATAC-seq
was performed as described previously8. In details, viable sorted 50,000 CD8+
T cells (Supplementary Fig. 1b) were washed with cold 1x PBS at 4°C and harvested
via centrifugation at 500 × g for 5 min at 4°C. These cells were resuspended in 50
μL of cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1%
IGEPAL CA-630) and nuclei were isolated by centrifugation at 500 × g for 10 min
at 4°C, followed by the transposition reaction in the transposase reaction mix
(25 μL 2× TD buffer, 2.5 μL Tn5 transposase (Illumina) and 22.5 μL nuclease-free
water) and incubated at 37°C for 30 min with mild agitation. DNA from the
transposition reaction were purified via a Qiagen PCR cleanup kit. PCR amplifi-
cation was performed using indexing primers (Supplementary Table 9) from the
Nextera kit (Illumina, San Diego, CA, USA). The optimal number of cycles in each
sample was determined via qPCR to stop the amplification before saturation of
indexed DNA libraries. After preparation, each library was quantified using a
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), based on the propor-
tion of index primer contamination interfering with the Illumina sequencer
(Illumina NextSeq500). Each library was then verified by quantitative PCR using
the KAPA Library Quantification Kit (Roche Applied Science, Basel, Switzerland).
The pool of indexed libraries was sequenced using Illumina NextSeq500 for 75
single-read bases and analyzed using the CASAVA (v. 1.8.2) base-calling software
(Illumina). Resultant reads were checked using the FASTQC software to assess the
quality of single-end or paired-end read sequences. For analysis, sequencing data of
each sample required a Phred quality score and total number of reads equal to or
greater than 30 (Q30) and 20 million, respectively. Detailed further analytical
method for ATAC-seq is provided as below.
Peak area calculation. Identification of accessible chromatin regions marked as
peaks was performed using the HOMER suite with the options for variable- or
fixed-width peaks. As previously described22, fixed-width peaks may be beneficial
in high-quality analysis for less biased large peaks and large datasets. Enrichments
beyond fixed-width peaks were excluded. During comparison of overall chromatic
accessibility (openness), the loss of tags within fixed ranges can dilute differences
between samples; to overcome this problem, all sample data were concatenated into
a single set and peak calling was performed using the HOMER suite for variable-
width peaks. Peak regions thus obtained correspond to each peak in each sample.
Instead of tag enrichments, peak area, representing the sum of tag enrichment, was
calculated using each bedGraph in the sample. Briefly, bedGraphs were generated
using the HOMER suite with the ‘makeUCSCfile’ command and the ‘-fragLength
147 -tbp 3 -style chipseq –raw’ options. The area of each peak was then calculated
by summing height per base pair in the peak range using a genome browser track





where dpq is the height per base pair at position p of the coordinate from start (Xq)
to end (Yq) of the qth peak. Finally, the peak areas were used to quantitatively
compare chromatin openness.
Control peak selection. To determine universal controls for normalization from
CD8+ T cells for ATAC-seq by the selection of peaks with low variability across
samples, ATAC-seq data including naive, effector memory, and central memory
CD8+ T cells from PBMCs (GSE89308) from healthy volunteers were used to
screen control peaks for normalization17. All sample data were concatenated into a
single set and peak calling was performed using the HOMER suite with variable-
width peaks to generate peak regions. Next, the area of selected peaks from each
CD8+ T-cell subset was calculated using bedGraphs, as described above. After
comparisons of naïve, effector memory, and central memory T-cell subsets, a total
of 32,485 overlapped peaks was obtained among all CD8+ T-cell subsets using
‘findOverlaps’. From these peaks, 4,798 peaks were selected that matched 100%
with DNase I hypersensitive (DH) uniform peaks and were located on the TSS or 5’
untranslated region (UTR)24. Among the selected peaks, 533 were consistent with
corresponding regions of ATAC-seq from peripheral blood (PB) CD8+ T cells used
in this study. The final overlapped peaks between CD8+ T-cell subsets (GSE89308)
of healthy volunteers and CD8+ T cells of patients with mGC (this study) satisfied
the following criteria. First, peak area indicating chromatin openness was quanti-
fied by summing height per base pair within the peak range; CV was calculated
using each sample peak area. In the 232 resulting ATAC peaks, CV was <0.3,
demonstrating low variance; peak width was <500 bp, demonstrating uniqueness.
Among these peaks, the 20 peaks with the highest average peak area were highly
evolutionarily conserved among 17 species according to the CisGenome browser31.
Calculation of normalization factor (F). To ensure a normally distributed
approximation, a discovery cohort C1 was randomly selected with a sample size of
n1 = 32, and a validation cohort C2 of size n2 = 52.






where m = 20 is the number of selected control peaks in the sample and ki is the
average height of the ith peak in the sample, calculated as follows:
ki ¼
the areaAi of the ith peak
the base length of the ith peak
The peak area was computed as the sum of enrichment within the peak. Because
the widths of selected peaks in each sample were considered equivalent, h was used
to represent the average amounts of selected control peaks for each sample.









where hai and hbj are the mean heights of the ith and jth samples in cohorts Ca and
Cb, respectively. The factor Fab compares the jth sample in cohort Cb with those of
cohort Ca. For example, F11 compares the jth sample in discovery cohort C1 with
those in discovery cohort C1; F12 compares the jth sample in discovery cohort C1
with those in validation cohort C2. A complete description of the basis and
derivation of the ATAC-seq normalization factor is provided in Supplementary
Fig. 4. The areas of peak regions and the genome browser track of each sample were
normalized by multiplying their normalization factors as follows:
Normalized area ¼ Fab ´Aq
where Fab is the normalization factor calculated from the jth sample in cohort Cb
with those in cohort Ca and Aq is the area of the qth peak in the jth sample in
cohort Cb.
Differential peak selection based on quantitative normalization. To select
differential peaks from ATAC-seq data of CD8+ T cells in patients with mGC who
were receiving anti-PD-1 therapy, a responder group was chosen that included
patients with complete response (CR) and partial response (PR); a non-responder
group was chosen that included only patients with progressive disease (PD).
Within the discovery cohort, the responder and non-responder groups were
classified based on the clinical decision at a certain time point after finishing
multiple cycles. Although it was difficult to classify patients with stable disease
(SD), these patients were excluded from the non-responder group and their peaks
were clearly distinct from those of the responder and non-responder groups5.
To increase the accuracy of identification of differential peaks between the two
groups, three peak callers were used to identify 2,560 peaks: the HOMER suite,
MACS2, and CisGenome. To quantitatively determine distinctive peaks between
the responder and non-responder groups, each sample peak was normalized by
multiplication with a normalization factor (F) calculated using three sets of
controls, ranked –5, –20, and –50 (Supplementary Table 5). Selected 68, 121 and
149 peaks by three sets of controls respectively showed the normalized average area
value of the cohort greater than the normalized average area value of total peaks
and the mean difference in area between the responder and non-responder groups
statistically significant (p < 0.05, Mann–Whitney U test). Only 67 peaks among
normalized peaks by three sets of controls satisfied these selection criteria
(Supplementary Fig. 6).
To define representative peaks among 67 peaks, three selection criteria were
used. 3 peaks were selected with higher average in the responder group. 3 peaks
were selected with lower variance among area values in the responder group. Lastly
the relative distance between the two groups were used; the area value of each peak
was divided by the largest area value among all samples, and then the relative
distance was calculated with the average of each group. 3 peaks with highest
relative distance between two groups were selected.
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Determination of cut-off for each target. For targets determined according to
normalized area values, the Cutoff Finder online tool (http://molpath.charite.de/
cutoff) was used to find the best cut-offs for use as predictive markers and response
guidelines in patients who were receiving anti-PD-1 therapy32. The threshold was
determined by comparing the responder and non-responder groups to minimize
the Euclidean distance between the ROC curves. The threshold of each differential
peak was determined as follows: first, the predictive performance of the threshold
for each differential peak was estimated according to the area under the ROC curve
(AUROC)33. Then, the discriminative ability of the threshold for both groups was
assessed by calculating their sensitivity, specificity, and accuracy (ACC)34. Finally,
the threshold of each differential peak was used in PFS analysis to determine the
clinical outcomes of anti-PD-1 therapy.
Optimal target combination. Using multiple markers can increase the predictive
power of a therapeutic response35. Therefore, nine selected peaks (target IDs) were
aligned in descending order of accuracy values. To convert the normalized area
value of each peak into a binary value, values above and below the threshold were
set to 1 and 0, respectively. Binary values were then multiplied by a value ranging
from 1 (lowest) to 9 (highest) based on the accuracy rank. These values were
defined as weighted scores, and applied to each sample as normalized chromatin
accessibility. The weighted scores were summed on the basis of the combination of
markers in each sample. Thus, the new cut-off was calculated using Cutoff Finder
for each combination of markers; the ROC analysis, discriminative ability, and PFS
analysis were computed between the responder and non-responder groups.
ATAC-seq alignment and peak calling. FASTQ data were processed using the
Trimmomatic software36 to increase read quality prior to alignment (per-base
sequence quality > 30) and then aligned to the primary assembly of the GRCh37/
hg19 human reference genome (chr1~22 and chrX) using the Bowtie2 software
with the parameters ‘-k 4 -N 1 -R 5 -end-to-end37. Finally, aligned reads were
converted into browser extensible data (BED) format using the ‘bedtools bamtobed’
parameter, and offset by +4 bp for the positive strand and –5 bp for the negative
strand; Tn5 transposase occupies 9 bp during transposition8. Three peak callers
were used to identify genome regions enriched with aligned reads: the Hyper-
geometric Optimization of Motif EnRichment (HOMER) suite25, Model-based
Analysis of ChIP-Seq 2 (MACS2)26, and CisGenome27. The aligned reads were
used for peak calling with the HOMER suite using ‘findPeaks’ and the ‘-style factor
-tbp 3 -region’ option, MACS2 with ‘callpeaks’ and the ‘--nolambda --nomodel
--shift 100 --extsize 200’ option, and CisGenome with the ‘Read extension length =
150 bp’, ‘Bin size = 50 bp’, ‘Max gap = 50 bp’, and ‘Min peak length = 100 bp’
options. During peak calling, artificially high regions were designated blacklisted
regions according to the Encyclopedia of DNA Elements (ENCODE) project.
Ultra-high signal artefact regions were retrieved from the comprehensive collection
(http://mitra.stanford.edu/kundaje/akundaje/release/blacklists/) and excluded from
the resultant peaks. Signal tracks were generated using the HOMER suite with the
‘makeUCSCfile’ command and the ‘-fragLength 147 -tbp 3-style chipseq -raw’
options, and visualized in the UCSC genome browser (https://genome.ucsc.edu/).
ATAC-Seq quality control: transcription start site (TSS) enrichment and
fraction of reads in peaks (FRiP). FRiP for each sample was the number of
aligned reads that overlapped the peak using “findOverlaps” divided by the total
number of aligned reads in the sample. To compute TSS enrichment score, each
TSS coordinates from HOMER suite “hg19.tss” was extended 2000 bp in both
direction and counted strand-corrected reads using “findOverlaps”. The number of
reads in each single base position bin was summed and divided by the average
number of reads at the TSS boundary (±1900–2000 bp from TSS). Finally, the TSS
enrichment score was the maximum enrichment value within ± 50 bp of TSS after
smoothing with a moving average for a window of 51 bps.
Statistical analyses. Data were expressed as means ± standard errors of the mean
(SEMs) and compared using the Mann–Whitney U test, Wilcoxon signed rank test,
and one-way ANOVA test. Progression-free survival (PFS) and median survival
were determined using the Kaplan–Meier method. Groups were compared using
the log-rank (Mantel–Cox) test. All statistical analyses were performed using
GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA) and R statistical
softwares (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-
project.org/). The Cutoff Finder (http://molpath.charite.de/cutoff/) was used to
determine an optimal threshold for chromatin openness to classify responder and
non-responder patients who were receiving anti-PD-1 therapy. ROC analysis
measured the predictive accuracy of selected peaks. In all analyses, P < 0.05 was
considered to indicate statistical significance.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The ATAC-seq data used in this study are available in the Gene Expression Omnibus
(GEO) database under accession code GSE142604. The public data used in this study are
available in the GEO database under accession code GSE89308, GSE74912, GSE118204,
and GSE117685. The remaining data supporting the findings of this study are available
within the Article, Supplementary Information or available from the corresponding
authors upon request.
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